Multiple Sclerosis | Current Treatment | US | 2016

Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and convenience. In just the past five years, six new MS DMTs have launched—one infusion, three injectable, and two oral—drastically altering physician prescribing practices and preferences. The Multiple Sclerosis | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets, while the Multiple Sclerosis | Current Treatment | US presents a snapshot of how U.S. neurologists are prescribing current DMTs and insight into the factors driving their prescribing habits.

Login to access report